

The information contained in these slides and any accompanying verbal presentation (together, the Presentation) has been prepared by Ponce De Leon Health (the Company) in connection with a proposed fundraising of ordinary shares in the capital of the Company.

If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising in investments of this kind. The information contained in this Presentation does not purport to cover all matters that may be relevant for the purposes of considering whether or not to make any prospective investment and is not intended to provide, and should not be relied upon, for accounting, legal or tax advice. This Presentation is supplied to you solely for information. This Presentation does not constitute an admission document, prospectus or listing particulars relating to the Company; it has not been approved by the Financial Conduct Authority, nor does it constitute or form part of any offer, invitation, inducement or commitment to, sell, issue, or any solicitation of any such offer or invitation to subscribe for, underwrite or buy, any shares in the Company or any of its affiliates to any person in any jurisdiction, nor shall it nor any part of it, nor the fact of its distribution form the basis of, or be relied on in connection with, or act as any inducement to enter into any contract or investment decision in relation to it.

This Presentation is for distribution in the UK only to persons authorised or exempted within the meaning of those expressions under FSMA 2000 or any order made under it or to those persons to whom these slides may be lawfully distributed pursuant to the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (Financial Promotion Order) as amended, including Certified High Net Worth Individuals as defined in article 48(2), Self-Certified Sophisticated Investors as defined in article 50A, Investment Professionals as defined in article 19(5) and high net worth entities as defined in article 49(2) of the Financial Promotion Order. Persons who do not fall within any of these definitions should not rely on these slides nor take any action upon them, but should return them immediately to the Company. The Presentation and any further confidential information made available to any recipient, either verbally or in writing, is confidential and is being supplied to you solely for your information and may not be reproduced, redistributed or passed to any other person or published in whole or in part for any purpose at any time. By accepting receipt of this Presentation, you agree to be bound by the limitations and restrictions set out in this Presentation. No reliance may be placed for any purpose whatsoever on the information contained in the Presentation or any assumptions made as to its completeness, accuracy or fairness, nor does the Company, its members, directors, officers, employees, agents, affiliates or representatives or advisers or any other person accept any obligation or responsibility to update or keep current the information contained in this Presentation. The information contained in the Presentation, which has not been independently verified, is confidential and for background purposes only and is subject to further verification, updating, revision and amendment and completion without notice. This Presentation does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an

investment in the Company. You are encouraged to seek individual advice from your personal, financial, legal, tax and other advisers before making any investment or financial decisions, subscribing for, or purchasing any securities.

Certain statements in the Presentation are forward-looking statements, and the Presentation itself has been based upon a number of assumptions, forecasts and projections of the Company which by their nature are forward looking. Forward-looking statements are typically identified by the use of forward-looking terminology such as believes, expects, may, will, could, should, intends, estimates, potential, anticipate, plans or assumes, or similar expressions, or by discussions of strategy that involve risk and uncertainties. By their nature, forward-looking statements, assumptions, forecasts and projections involve a number of risks and uncertainties, and in some cases are based on estimates and incomplete information, that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements or by the Presentation as a whole. These risks and uncertainties, and the impact they have on the assumptions, forecasts and projections contained in the Presentation, could adversely affect the outcome and financial effects of the plans and events described in the Presentation.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of their respective agents, affiliates, representatives, advisers, employees or its directors or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this document and no responsibility or liability is accepted by any person for any loss however arising from any use of, or reliance on, or in connection with, this document or its contents or otherwise arising in connection therewith. Notwithstanding this, nothing in this paragraph shall exclude liability for any such representation or warranty made fraudulently.

The distribution of this document in certain jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such requirements or restrictions. Any such distribution could result in a violation of the law of such jurisdictions. Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America or its territories or possessions (United States), or distributed, directly or indirectly, in the United States, or to any U.S. Person as defined in Regulation S under the Securities Act 1933 as amended, including U.S. resident corporations, or other entities organised under the laws of the United States or any state of the United States, or non-U.S. branches or agencies of such corporations or entities. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed in Canada, Australia, Japan, South Africa or the Republic of Ireland, or any other jurisdiction which prohibits such taking in, transmission or distribution, or to any person resident in such jurisdictions (including corporations or other entities organised under the laws of such jurisdictions, or branches or agencies of such corporations or entities outside of those jurisdictions) except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of United States or other national securities laws.



DECREASING BIOLOGICAL AGE FOR ALL



When we decrease biological age people live healthier for longer. This benefits the individual, their family, healthcare provider, insurer, and their government.

*Dr. Brian Kennedy –
Chief Science Officer, PDL Health
Director and Professor, Center for Healthy Aging,
National University of Singapore*




PROBLEM

Lifespan vs. healthspan – a new approach is needed


Lifespan is increasing, adding years of life, but living in poor health

To add productive years living in good health, we need to extend healthspan



SOLUTION

Extending healthspan by decreasing biological age



HOW TO DECREASE BIOLOGICAL AGE?

Lifestyle/diet improvements	Challenging in practice for majority of population
Therapeutics	Not available – aging not a disease
Supplements	Many health claims but no proof



THE SCIENCE: What causes human aging and how does Rejuvant work?



THE PROBLEM: Aging is a software problem, not a hardware problem:

- Aging is a software problem, not a hardware problem:
 - The genome is the hardware
 - The epigenome is the software
- Aging is caused by changes to the epigenome, due to damage and the passage of time.

THE SOLUTION: What causes human aging and how does Rejuvant work?

- Lifespan is largely epigenetically determined, rather than genetically pre-determined
- Rejuvant rebalances your DNA methylation pattern (the gold standard for measuring biologic age*) to that of a younger you, resetting gene expression, thus decreasing epigenetic aging:



It upregulates good gut bacteria and down regulates harmful bacteria



Increases stem cell production



Blocks cytokine signaling of senescent cells, thus reducing chronic inflammation



Increases the ability of red blood cells to carry oxygen, increasing endurance and healing


* S. Horvath and K. Raj, Nature Reviews, Genetics, Vol. 19, 2018

THE JOURNEY TO AKG – Core thesis: the polytherapy approach

Combinations not compounds:

Rejuvant is a natural cocktail of GRAS components already made in our bodies, leveraging synergy among these components, that touch multiple aging pathways.

Our discovery process and roadmap:



SOLUTION: REJUVANT

The first and only available supplement **proven** to decrease biological age in humans



- One dose a day supplement (male and female product)
- Human data showing an **8 year decrease** in biological age after 7 months of use
- Non-pharmaceutical (GRAS) compounds
- No anticipated consumer safety issues
- US patents pending, multiple foreign patents pending
- No anticipated regulatory approval process

PROGRESS BASED ON EVIDENCE



	Sept 2019	Nov 2021	Q3 2022	Post-funding
	Research study ✓	Pilot study ✓	Safety study ✓	Marketing claims study
Species	Mouse	Human	Human	Human
Cohort size	4 cohorts	42 adults	45 adults placebo 45 adults control	100 adults placebo 100 adults control
Cohort attributes	Genetically and chronologically identical mice	Mixed: older and sicker adults	Mainly healthy adults	55+ years old, no limit on co-morbidities, no radiation therapy, no Metformin
Placebo controlled	YES	NO	YES	YES
Trial attributes	Lab study of colonies of genetically identical mice	Human efficacy pilot study to test introduced CaAKG	Human safety study for biological age reduction and target user profile	Human efficacy study for biological age reduction on target market
Decrease in biological age (%) average	-12%	-11%	n/a	-13%*
Decrease in biological age (years human equivalent) average	-9 years	-8 years	n/a	-10 years*
Enabling us to ...	Progress to human pilot study >>	Progress to human safety study >>	Progress to marketing claims launch study >>	First ever supplement to launch with proven age-reduction claims


* Estimated efficacy based on target market user profile




Differences between test and control sub-groups

Genetically identical; age Identical:

Control



Test: CaAKG in feed



Rejuvant's CaAKG formula has a profound effect, on average:

Increasing lifespan by 12%

Increasing healthspan by 41%

Compressing morbidity by 46%

Statistically significant for postponing the onset of:

Frailty, graying of hair/hair loss, curvature of the spine, tremors, gait disorders

Animals begin regimen at human equivalent age 55; photos taken at human equivalent age 70





Priority Research Paper | Advance Articles

Published in Aging on November 30, 2021

“Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAgeDNA methylation test”

Oleksandr Demidenko^{1, *}, Diogo Barardo^{2, *},
Valery Budovskii¹, Robb Finnemore³, Francis
R. Palmer III³, Brian K. Kennedy^{2,3,4,5}, Yelena
V. Budovskaya¹

Remarkably, individuals showed an average decrease in biological aging of 8 years (p -value=6.538x10⁻¹²).

Furthermore, the supplementation with Rejuvant® is robust to individual differences, as indicated by the fact that a large majority of participants decreased their biological age. Moreover, we found that Rejuvant® is of additional benefit to chronologically and biologically older individuals.


While continued testing, particularly in a placebo-controlled design, is required, **the nearly 8-year reversal in the biological age of individuals taking Rejuvant® for 4 to 10 months is noteworthy, making the natural product cocktail an intriguing candidate to affect human aging.**



2nd human study:

Safety study learnings:

- Rejuvant is safe
- MTHFR gene inhibits the benefits of Rejuvant
- Biologic age should be equal or greater than chronological age
- Older subjects respond better
- Metformin and berberine inhibit the benefits of Rejuvant










Protocol: applying on our knowledge we expect to have a very successful definitive study

- 2 sites (will try to get both in Florida near PDL office)
- Each site recruits 100 for 80 subjects (assume 20% drop out rate) ... Total 160 ½ study ½ control
- We want older, less healthy participants this time around
 - Subjects must not be biologically younger than their chronological age at T0 by more than 2 years
 - Subjects cannot be taking Metformin or Berberine one year prior to, or during the study
 - Subjects cannot be undergoing any form of radiation therapy
 - Subjects cannot be a stage 3 or later cancer patient
 - Female subjects cannot be pregnant, or planning on becoming pregnant during the study period
 - Subjects cannot be taking opioids one year prior, or during the study period
 - Subjects must reside in the US, and agree to allow the company to use any data gathered during the study in blinded form
 - Subjects agree to the best of their ability to keep their habits, diet, exercise etc., consistent from T0 to T6



We now know who Rejuvant has the most benefit to:

	Persona GenZ <24yrs	Millennial <40yrs	Gen X <56yrs	Gen X <56yrs	Boomers <75yrs	Boomers <75yrs	Silent/greatest >75yrs
							
Character	Olivia	Ashley	Mike	Chad	Sally	David	Anne
Persona	Olivia has a mild interest in health and well being, she has heard of biohacking but isn't sure what it's really all about.	Ashley likes his sport and tries to keep on top of his weight - mixing a busy career with time in the gym and with friends socialising.	Mike has a Whoop band and a plan! He's nearly given-up meat and is a marathon runner. He's keen to stay on top of his weight and fitness.	He's considering ways to age well but he enjoys takeaways and socialising, anything easy and proven gets his attention.	Sally has had a few health scares but she's fine now. She loves her grandchildren and wants to invest in products that help her stay healthy.	David has diabetes, heart disease and early-stage prostate cancer. A large percentage of his income covers healthcare costs.	Anne is doing really well for her years. She has a lot of friends and still is active physically and plays bridge twice a week.
Rejuvant relevance	Low	Low	Medium	High	High	High	High
Average spend on longevity supplements/month				\$186		\$275	
Top reason for supplementing				Preventing age-related diseases		Preventing a vitamin deficiency	
Top reason to buy a supplement	Proven effectiveness against an aging outcome in human clinical trials						


Professor Andrew Scott:

The average American would pay \$242,000 for one extra year of good health

U.S. SUPPLEMENTS – A HEALTHY GROWTH CATEGORY




U.S. supplement sales grew 14.5% to \$55.8B in 2020, and est. 5.3% to \$58.7B in 2021



Source: Nutrition Business Journal 2021 (\$ billion, consumer sales)

Specialty supplements are projected to see the highest growth over the next several years



Source: Nutrition Business Journal

GO TO MARKET

We will operate an omni-channel approach to marketing, initial focus will be on building our own direct-to-consumer model to build loyalty and reordering/re-testing protocols:

Ecommerce

- SEM, Social Media, Influencers, email, content for SEO
- Affordable, respond quickly to market, target consumers across multiple platforms

Amazon

- Alternative way to shop, have developed consumer's trust
- Nutritional brands have seen major growths

Professional

- Target Doctors and clinics
- Potentially stronger formulation

Monthly subscription pricing with complimentary DNA testing to test progress:

\$109.95



One-time monthly purchase:
\$149.95

Retail

- Niche - GNC and Vitamin Shoppe
- Mass - CVS, Walmart, Target, Grocery Stores

TV advertising

- Reaches a large audience in a short amount of time, ability to target
- Creates strong brand recognition that influences ecommerce and retail

International

- Create distributorships across Canada, Europe and Asia
- Allows for quicker expansion into international markets



TRACTION




Rejuvant is outperforming across the board

	Rejuvant	Industry average
LTV (lifetime value of customer)	\$875 (after 24 months)	Target \$300 (after 24 months)
CAC (customer acquisition cost)	\$250 in test mode	2 to 2.5x retail price in non-test mode
LTV/CAC	3.5:1	3:1 industry benchmark
Continuity repurchase rates	91%	40-50%
AOV (average order value)	\$135	\$30-100
Return on acquisition spend	All initial start groups are positive	9-18 months
Repeat orders in start year	7.1 in initial 12 months	2-3 in 12 months

GO TO MARKET PHASE 2: INGREDIENT LICENSING

Our testing and approvals rigor places us in a strong position to license our proven product into multiple product channels (both B2B and B2C):



TEAM: PROVEN LEADERSHIP



Tom Weldon, Founder & CEO

- *35 years in medtech, founder of over a dozen companies*
- *Experienced VC with top quartile Accuitive Medical Ventures*
- *Created over \$2.7B in shareholder value in companies personally founded*



Dr. Brian K. Kennedy, Chief Science Officer

- *Director and Professor, Center for Healthy Aging, National University of Singapore*
- *Published over 60 manuscripts in Nature, Cell, Science, etc...*
- *Former CEO of The Buck Institute for Research on Aging*



TEAM: DEEP FUNCTIONAL EXPERIENCE



FINANCE – Robb Finnemore, CFO

- Senior VP of Finance - Mas Energy (overseeing \$100mm fund raise)
- 20 years in finance functions at Healogics, KPMG, Deloitte

CLINICAL DEVELOPMENT – Francis Rogers Palmer III M.D., Chief Medical Officer

- Board-certified facial plastic reconstructive surgeon with 20 years of CMO/medical director experience
- Past director and professor emeritus facial plastic surgery at University of Southern California

MARKETING - Annette Moore, Vice President of Marketing

- VP of Marketing - Healthy Directions
- Executive Marketing Director - Nutranext

R&D - Stanley Lech, Vice President of R&D

- President Chief Strategy & Science Officer - PharmaMax Corporation
- Global Head of R&D and Innovation – Sanofi Consumer Healthcare
- Global VP, Wellness R&D - GlaxoSmithKline

SALES - Mr. A., Vice President of Sales

- Roles as Director of Global Sales, President of US division and VP at industry corporations

OPERATIONS - Mr. J., Vice President of Operations

- Roles as VP of Growth & Business Head and Logistics & Project Manager at industry corporations

BUSINESS DEVELOPMENT - Rob Eddy, CPA, Chief Business Officer

- CFO & CIO -The Holding Company of the Villages
- Partner (Assurance) - PWC

INTELLECTUAL PROPERTY


Our IP position is solid with multiple applications in process to enable us to protect our market position and scale-up license revenue opportunities:

Reference	Description	Status
PCT/US2018/029455 WO2018/200736	Singapore Patent No. SG11201909967QA	Issued Patent
PCT/US2018/029455 WO2018/200736	Formulations For Extending Healthspan	Pending Application
PCT/US2019/052498 WO2020/068705	Process Of Making Calcium Alpha-Ketoglutarate	Pending Application
PCT/US2020/036987 WO2020/252014	Sustained-Release Compositions Of Alpha-Ketoglutarate	Pending Application
PCT/US2020/036974 WO2020/252005	Methods And Compositions For Altering Senescence Associated Secretory Phenotype	Pending Application
PCT/US2021/040257	Compositions And Methods For Treating Age-Related Illness	Pending Application
Additional related Patent Applications are pending in other countries		
US Reg. No. 6,034,668	REJUVANT (Trademark)	Registered in the US and in other countries
US Reg. No. 6,020,135	LIFETABS (Trademark)	Registered in the US and in other countries



FINANCIAL PROJECTIONS

Near-term visibility to cash flow break-even in <24 months, diversified channel strategy



- Customers at end of year 5: 108k
- Gross margin: 64%-67%
- Cash flow breakeven in 4Q2023

Lifetime revenue per customer: \$880

CAC: \$300 decreasing to \$150

LTV/CAC increasing to 5.9x

INVESTMENT OPPORTUNITY



Raising \$10-\$20M of equity in Series C Round

- Prior funding:
 - \$11.4mm raised to date
 - Founding team retains 43% of equity
- Milestones for this round:
 - Build out senior management team
 - Begin approval process in China
 - Begin paid media campaign
 - Develop new products
 - Expand distribution channels
- Exit:
 - Break even with \$16M total new equity
 - Liquidity through IPO/SPAC/M&A possible within 2 years

- Source and use of funds to reach cash flow breakeven in ~24 months

Source and Use	USD\$
Source of Funds	
Opening Cash	\$0.0
Series C	\$16.0
Net cash from Sales	\$27.6
	\$43.6
Use of Funds	
Customer Acquisition	-\$15.0
G&A	-\$16.4
IPO/SPAC readiness	-\$2.0
Regulatory approval: China	-\$3.8
Working Capital	-\$6.4
	-\$43.5

LONGEVITY FINANCING LANDSCAPE



Company	Series A		Series B		Series C		Date of	Commercial	Clinical
	\$M	Valuation	\$M	Valuation	\$M	Valuation	latest round	Product	Proof (human age reversal)
Juvenescence	53	196	100	400			8/19/2019	Yes	No
BioAge	11	33	23	62	90	175	12/3/2020	No	No
Life Biosciences			50	450	82		9/28/2021	No	No
Ossium Health			63	120			3/18/2021	No	No
Rejuveron	17	49	39	215			2/24/2022	No	No
Elysium Health			20	86	40	200	9/26/2021	Yes	No
ResTORbio	25	15	40	200			11/30/2017	No	No
PDL Health		15		50		150	Q3 2022	Yes	Yes

PDL is an unprecedented opportunity to invest in a clinically proven longevity product - commercially available, ready for scale-up


GROWING M&A APPETITE FOR SUPPLEMENTS

Strategics have been voracious buyers of supplement deals



<u>Date</u>	<u>Target</u>	<u>Business</u>	<u>Strategic Acquirer</u>	<u>Transaction (\$MM)</u>
2/1/2021	DuPont Nutrition & Health	Food ingredients	IFF	15,954
8/9/2021	The Bountiful Company	Nutritional supplements	Nestle	5,750
11/30/2018	Merck Consumer Health	OTC health and nutritional supplements	P&G	3,375
3/1/2018	Atrium Innovations	Nutritional supplements	Nestle	2,300
7/1/2019	UPSA (Bristol-Myers)	OTC health and nutritional supplements	Taisho Pharma	1,600
12/8/2020	Emisphere Technologies	Medical food	Novo Nordisk	1,350
10/1/2021	Bettera Wellness	Nutritional supplements	Catalent	1,000
3/12/2018	Nutranext	Nutritional supplements	Clorox	700
3/31/2021	Takeda OTC	OTC health and nutritional supplements	Orifarm	670
2/20/2019	Cytosport (Hormel)	Nutritional supplements	PepsiCo	465

Deal volume in nutritional supplement M&A reached its highest level in 2021



Source: PitchBook Data



EXECUTIVE SUMMARY



- Rejuvant is the first and only available supplement proven to decrease biological age in humans
- All natural endogenous components/ingredients
- Proof of concept in animals; now proven in humans
- Fast growing global market for specialty supplements
- Massive unmet demand for aging reversal supplements
- Traction with attractive recurring revenue business model
- Led by proven business builder and leading authority on aging
- Launching in a strategic landscape hungry for healthy aging and nutritional supplement deals
- Unprecedented opportunity to invest in a clinically proven longevity commercially ready product in a \$10mm Series C round with visibility to liquidity/exit in two years

Longevity.Technology®

Thank You!

Harry Robb

First Longevity Ltd

harry@longevity.technology

+44 7795042764

Henry (Harry) Robb is seconded to Prospect Capital Ltd. which is authorised and regulated in the UK by the FCA reg: 515599 and as an approved Foreign Associated Person of First Longevity Ltd, as the agent in respect of the Placement in the United States (permitted by SEC Rule 15a-6) is Marco Polo Securities Inc. (CRD#46561), a non-affiliated broker-dealer registered with FINRA and The SEC.

Please note that if you have any questions about this arrangement or wish to contact Marco Polo directly, you can contact Mathew McConnell at 914-960-9711 or Daniel Ibarra at 347-773-4959, 917-359-1193 and at dibarra@mpsecurities.com

Ponce De Leon Health has appointed First Longevity Ltd to introduce Ponce De Leon Health to suitable professional investors.

Appendices




OPINION LEADER SUPPORT FOR REJUUVANT/AKG




David Sinclair
Author of “Lifespan”
Professor of genetics at
Harvard Medical School
Host of the “Lifespan” podcast

David Sinclair recently discussed being a non-paid user of Rejuvant’s AKG on the following podcasts:

The Gabby Reece Show,
March 28, 2022, at 38min30s




The School of Greatness by Lewis Howes,
February 23, 2022, at 46min55s






Protocol:



Result:



REJUVANT: the upside of decreasing aging



Left to right: Andrew J Scott (London Business School), David Sinclair (Harvard Medical School), Martin Ellison (University of Oxford)

Professors Scott, Sinclair and Ellison's economic model:



- Estimates that targeting aging has larger economic gains than eradicating individual diseases
- Calculates the value to the global economy of a slowdown in aging that increases life expectancy by one year as:

\$38,000,000,000,000

<https://longevity.technology/the-trillion-dollar-upside-to-longevity/>

SPECIALTY AND HERBS ARE GROWTH LEADERS

Specialty Supplements and Herbs/Botanicals have been the most consistent growers and are projected to see the highest growth over the next several years




Source: Nutrition Business Journal 2021

Confidential



EXCEPTIONAL WILLINGNESS TO PAY FOR LONGEVITY

What percent of your wealth would you sacrifice to guarantee an extra 10 years of healthy life?



Source: The Century Club, UBS Private Bank



Legal Notices

This presentation is being delivered to prospective investors on a confidential basis so that they may consider an investment in Ponce De Leon Health (the "Company"). These materials do not purport to be all-inclusive or to contain all the information that a prospective investor may desire in investigating the Company. These materials are merely for preliminary discussion only and may not be relied upon for making any investment decision with respect to the Company. Rather, prospective investors should rely upon the Company's private placement memorandum (the "PPM") and their own independent investigation of the Company. In the event that any of the terms of this presentation are inconsistent with or contrary to the PPM, the PPM shall control.

Neither the SEC nor any commissioner of any such state authority or other jurisdiction has passed upon the accuracy or adequacy of this presentation, and any representation to the contrary is unlawful. This presentation does not constitute an offer to sell or a solicitation of interest to purchase any securities or investment advisory services in any state or in any other jurisdiction in which such offer or solicitation is not authorized.

This presentation may contain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. Because such forward-looking statements involve risks and uncertainties, actual results of the Company may differ materially from any expectations, projections or predictions made or implicated in such forward-looking statements. Prospective investors are therefore cautioned not to place undue reliance on such forward-looking statements.

This presentation speaks as of the date hereof and neither the Company nor any affiliate or representative thereof assumes any obligation to provide any recipient of this presentation with subsequent revisions or updates to any historical or forward-looking information contained in this presentation to reflect the occurrence of events and/or changes in circumstances after the date hereof.

